Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258876 | 0.92 | ROCK2 (0.37) | ROCK2ALDH1A1LMNAHPGDALOX12 | |
| SCHEMBL4446430 | 0.82 | — | — | |
| SCHEMBL4271996 | 0.81 | CHRNB2 (0.31) | — | |
| SCHEMBL12804482 | 0.80 | MAPKAPK2 (0.32) | — | |
| SCHEMBL4263939 | 0.78 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL4265887 | 0.75 | CDC7 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL4260849 | 0.74 | MAPKAPK2 (0.32) | — | |
| SCHEMBL6794548 | 0.73 | — | — | |
| SCHEMBL6792481 | 0.73 | PTGER1 (0.32) | — | |
| SCHEMBL6796245 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | ROCK2 317/4885HRH3 1936/4885HRH4 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.